Rhythm Pharmaceuticals (RYTM) Net Equity Issued and Repurchased (2017 - 2025)

Rhythm Pharmaceuticals (RYTM) has reported Net Equity Issued and Repurchased for 7 consecutive years, with -$188.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$188.7 million; the TTM figure through Mar 2026 stood at -$34.0 million (down 129.32% YoY), while the FY2024 annual figure was $138.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased retreated to -$188.7 million in Q4 2025 per RYTM's latest filing, from $154.6 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $161.7 million in Q1 2021 and bottomed at -$188.7 million in Q4 2025.
• Historically, Net Equity Issued and Repurchased has averaged $18.1 million across 4 years, with a median of $14.1 million in 2022.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 282860.0% — and 2023, when it sank 445.7%.
• Rhythm Pharmaceuticals' Net Equity Issued and Repurchased stood at -$5000.0 in 2021, then jumped by 282860.0% to $14.1 million in 2022, then tumbled by 445.7% to -$48.9 million in 2023, then tumbled by 285.99% to -$188.7 million in 2025.
• Business Quant data shows RYTM's Net Equity Issued and Repurchased at -$188.7 million in Q4 2025, $154.6 million in Q3 2025, and $34.0 million in Q1 2025.